View ValuationMedWellAI 将来の成長Future 基準チェック /06現在、 MedWellAIの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Software 収益成長19.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • May 08MedWellAI Inc. Reconfirms Yearly Revenue GuidanceMedWellAI Inc. reconfirmed yearly revenue guidance of $2.3 million.お知らせ • May 15Integrated Ventures, Inc. Provides Revenue Guidance for the Full Year 2021Integrated Ventures, Inc. provided revenue guidance for the full year 2021. For the year, total revenues for 2021 are projected to be in $2.3 million to $2.4 million range with a 60%+ gross margin.すべての更新を表示Recent updatesお知らせ • May 08MedWellAI Inc. Reconfirms Yearly Revenue GuidanceMedWellAI Inc. reconfirmed yearly revenue guidance of $2.3 million.お知らせ • Feb 19MedWellAI Inc. announced delayed 10-Q filingOn 02/18/2026, MedWellAI Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 11MedWellAI Inc. (OTCPK:MWAI) signed a letter of intent to acquire Resonate Blends, Inc. (OTCPK:KOAN) from FirstFire Capital Management LLC.MedWellAI Inc. (OTCPK:MWAI) signed a letter of intent to acquire Resonate Blends, Inc. (OTCPK:KOAN) from FirstFire Capital Management LLC on February 10, 2026. In a related transaction MedWellAI signed a letter of intent to acquire Ageless Cosmetic Surgery Centers, Inc. The transaction is subject to consummation of due diligence investigation. The expected completion of the transaction is within 60 days.お知らせ • Oct 02MedWellAI Inc. Auditor Raises 'Going Concern' DoubtMedWellAI Inc. filed its Annual on Sep 30, 2025 for the period ending Jun 30, 2025. In this report its auditor, M & K CPAS, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Oct 01MedWellAI Inc. announced delayed annual 10-K filingOn 09/30/2025, MedWellAI Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 19MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD to Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused on $24.46 Billion Corporate Wellness MarketMedWellAi Inc. confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai - Nationwide B2B and B2C Healthcare and Wellness Telemedicine Platform, with main focus on corporate healthcare benefits market. Scheduled to go live in October, 2025, TeleMD is designed to deliver a comprehensive telehealth primary care that is affordable and accessible for everyone. Clients will be able to access all the healthcare care they need through TeleMd's platform and technology, easy-to-use desktop and mobile apps, resulting in getting timely healthcare advice, eliminating travel and wait time to schedule appointments. This platform will offer (1) affordable monthly subscription plans (retail + corporate clients) with unlimited access to the healthcare providers and certified telehealth therapists, (2) nationwide 365/24/7 access via smart device or desktop, (3) no co-pays, no cancelation or any other additional fees/charges. With innovative stack that includes Cloudflare, Google Font API, and Bootstrap, TeleMD is committed to leveraging technology for delivering healthcare services. BrighterMD solutions and their technology approach, provide an opportunity for TeleMD to offer their tech-savvy corporate clients with effective options on how to integrate the latest healthcare solutions into their current systems. TeleMD Ai is focused on two markets segments: Business-To-Public And Business-To-Business. Users will have access to unlimited appointments, 24 hours a day from the comfort of their home or office. B2B - Discounted Group Pricing for Companies: TeleMD delivers affordable healthcare for employees, while reducing premiums with high quality comprehensive telemedicine solution. Now, employers can offer extra benefits with primary care online, provide employees and their families with unlimited private appointments that will't be shared with insurers or employers. All employees can quickly and conveniently access team of medical professionals, as frequently as they need. TeleMD is a simple and effective addition to any benefits package. Enrolling employees into the program is available via API integration, or via EDI file transfer. Simple to set up, easy to use. Company's goal is to provide a seamless, robust and affordable healthcare solution for employers to offer their employees. By choosing TeleMD's telehealth services, employers will reduce insurance premiums, while offering convenient and extensive primary care and mental health support to employees that they can use whenever they need it. Additional services include: (1) Financial and Legal Consultations, (2) Life Coaching, (3) Medical Advocacy and (4) Nutritional Counseling. TeleMd's AI-enhanced platform will offer new ways to provide mental support and care. It will feature Ai Agent that can identify signs of depression or distress and provide on-the-go support, and connect individuals with human therapies when needed. 90% of chronic condition meds home delivered at a $0 copay. 125 acute meds at any pharmacy at a $0copay. TeleMD offers diabetes program at no added cost and OTC meds at a discount. Members save up to 80% on prescriptions; at most major RX retailers as well as 80% on any lab work at any Quest Diagnostics location. Bilingual Services: TeleMD differentiates itself by offering bilingual (English+ Spanish) Board-Certified doctors and mental health therapists. This FREE feature could be a valuable selling point for many corporations with diverse workforces that seek healthcare solutions that cater to employees with varying language needs, presenting a market niche to target. Currently FDA Registered with clinical trials completed. This platform l allows clients to take complete control of everyday health and wellness. Doctegrity is focused on providing (1) affordable telemedicine: cost-effective way for employers to provide healthcare benefits to their employees, including those who may not have traditional insurance coverage, (2) comprehensive solutions and care: their services include 365/24/7 access to board-certified physicians and licensed therapists for both physical and mental health needs and mental health therapists.お知らせ • May 16Integrated Ventures, Inc. announced delayed 10-Q filingOn 05/15/2025, Integrated Ventures, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 16Integrated Ventures, Inc. announced delayed 10-Q filingOn 11/15/2024, Integrated Ventures, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Sep 30Integrated Ventures, Inc. Auditor Raises 'Going Concern' DoubtIntegrated Ventures, Inc. filed its 10-K on Sep 28, 2022 for the period ending Jun 30, 2022. In this report its auditor, M & K CPAS, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • May 15Integrated Ventures, Inc. Provides Revenue Guidance for the Full Year 2021Integrated Ventures, Inc. provided revenue guidance for the full year 2021. For the year, total revenues for 2021 are projected to be in $2.3 million to $2.4 million range with a 60%+ gross margin.お知らせ • Jan 24Integrated Ventures, Inc. announced that it expects to receive $3 million in funding from BHP Capital NY, Inc.Integrated Ventures, Inc. (OTCPK:INTV) announced that it has executed a binding term sheet for a private placement of convertible preferred series C stock led by returning investor BHP Capital NY, Inc. for gross proceeds of $3 million on January 22, 2021. The transaction will be completed in tranches and the company expects to receive an initial tranche in next few days. The investor has received a right to convert newly registered preferred stock into common shares at a fixed conversion price of $0.068.お知らせ • Sep 22Integrated Ventures, Inc. announced that it expects to receive $1 million in funding from Eagle Equities, LLCIntegrated Ventures, Inc. (OTCPK:INTV)announced that it has entered into a securities purchase agreement with Eagle Equities, LLC for private placement of a 6% convertible redeemable note due February 4, 2022 for gross proceeds of $1,000,000 on August 4, 2020. The note will carry a fixed interest coupon of 6% per annum, issued at a discount of 8% and will mature on February 4, 2022. The note provides the holder the right to convert the note into shares of the company’s common stock at a price for each share of common stock equal to the lower of 70% of market price as reported on the National Quotations Bureau OTC Market exchange which the company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen prior trading days including the day upon which a notice of Conversion is received by the company. The company will receive funding in tranches, $250,000 in its first and second tranche. The company shall not consummate the sale of any convertible securities until the earlier of 30 days after purchase of the second tranche or, if the second tranche is not funded, then 60 days after the closing date of the first tranche. The company will pay $6,000 as legal fees in its first and second tranche. The company issued the note pursuant to exemption provided under Regulation D. On the same day, the company has received its first tranche of $250,000. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、MedWellAI は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:MWAI - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20262-200N/A12/31/20252-3-1-1N/A9/30/20251-3-1-1N/A6/30/20251-3-1-1N/A3/31/2025-4-2-2-2N/A12/31/2024-3-1-2-2N/A9/30/2024-1-1-4-3N/A6/30/2024N/A-10-4-4N/A3/31/20246-32-4-4N/A12/31/20236-34-5-5N/A9/30/20234-35-3-3N/A6/30/20234-27-3-3N/A3/31/20233-6-3-3N/A12/31/20223-4-4-1N/A9/30/20225-3-7-1N/A6/30/20227-1-80N/A3/31/20227-5-150N/A12/31/20216-22-17-1N/A9/30/20214-21-14-1N/A6/30/20212-23-13-2N/A3/31/20211-18-4-1N/A12/31/20200-2-1-1N/A9/30/20200-2-1-1N/A6/30/20200-1-1-1N/A3/31/20200-8-1-1N/A12/31/20190-8N/A-1N/A9/30/20190-8N/A-1N/A6/30/20190-10N/A-1N/A3/31/20190-6N/A-1N/A12/31/20180-6N/A-1N/A9/30/20180-7N/A-1N/A6/30/20180-6N/A-1N/A3/31/20180-3N/A-1N/A12/31/20170-2N/A0N/A9/30/2017N/A-1N/A0N/A6/30/2017N/A-2N/A0N/A3/31/2017N/A-2N/A0N/A12/31/2016N/A-5N/A0N/A9/30/2016N/A-5N/A0N/A6/30/2016N/A-5N/A0N/A3/31/2016N/A-4N/A-1N/A12/31/2015N/A-1N/A0N/A9/30/2015N/A0N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MWAIの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MWAIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MWAIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MWAIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MWAIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MWAIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 18:01終値2026/05/22 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedWellAI Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 08MedWellAI Inc. Reconfirms Yearly Revenue GuidanceMedWellAI Inc. reconfirmed yearly revenue guidance of $2.3 million.
お知らせ • May 15Integrated Ventures, Inc. Provides Revenue Guidance for the Full Year 2021Integrated Ventures, Inc. provided revenue guidance for the full year 2021. For the year, total revenues for 2021 are projected to be in $2.3 million to $2.4 million range with a 60%+ gross margin.
お知らせ • May 08MedWellAI Inc. Reconfirms Yearly Revenue GuidanceMedWellAI Inc. reconfirmed yearly revenue guidance of $2.3 million.
お知らせ • Feb 19MedWellAI Inc. announced delayed 10-Q filingOn 02/18/2026, MedWellAI Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 11MedWellAI Inc. (OTCPK:MWAI) signed a letter of intent to acquire Resonate Blends, Inc. (OTCPK:KOAN) from FirstFire Capital Management LLC.MedWellAI Inc. (OTCPK:MWAI) signed a letter of intent to acquire Resonate Blends, Inc. (OTCPK:KOAN) from FirstFire Capital Management LLC on February 10, 2026. In a related transaction MedWellAI signed a letter of intent to acquire Ageless Cosmetic Surgery Centers, Inc. The transaction is subject to consummation of due diligence investigation. The expected completion of the transaction is within 60 days.
お知らせ • Oct 02MedWellAI Inc. Auditor Raises 'Going Concern' DoubtMedWellAI Inc. filed its Annual on Sep 30, 2025 for the period ending Jun 30, 2025. In this report its auditor, M & K CPAS, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Oct 01MedWellAI Inc. announced delayed annual 10-K filingOn 09/30/2025, MedWellAI Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 19MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD to Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused on $24.46 Billion Corporate Wellness MarketMedWellAi Inc. confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai - Nationwide B2B and B2C Healthcare and Wellness Telemedicine Platform, with main focus on corporate healthcare benefits market. Scheduled to go live in October, 2025, TeleMD is designed to deliver a comprehensive telehealth primary care that is affordable and accessible for everyone. Clients will be able to access all the healthcare care they need through TeleMd's platform and technology, easy-to-use desktop and mobile apps, resulting in getting timely healthcare advice, eliminating travel and wait time to schedule appointments. This platform will offer (1) affordable monthly subscription plans (retail + corporate clients) with unlimited access to the healthcare providers and certified telehealth therapists, (2) nationwide 365/24/7 access via smart device or desktop, (3) no co-pays, no cancelation or any other additional fees/charges. With innovative stack that includes Cloudflare, Google Font API, and Bootstrap, TeleMD is committed to leveraging technology for delivering healthcare services. BrighterMD solutions and their technology approach, provide an opportunity for TeleMD to offer their tech-savvy corporate clients with effective options on how to integrate the latest healthcare solutions into their current systems. TeleMD Ai is focused on two markets segments: Business-To-Public And Business-To-Business. Users will have access to unlimited appointments, 24 hours a day from the comfort of their home or office. B2B - Discounted Group Pricing for Companies: TeleMD delivers affordable healthcare for employees, while reducing premiums with high quality comprehensive telemedicine solution. Now, employers can offer extra benefits with primary care online, provide employees and their families with unlimited private appointments that will't be shared with insurers or employers. All employees can quickly and conveniently access team of medical professionals, as frequently as they need. TeleMD is a simple and effective addition to any benefits package. Enrolling employees into the program is available via API integration, or via EDI file transfer. Simple to set up, easy to use. Company's goal is to provide a seamless, robust and affordable healthcare solution for employers to offer their employees. By choosing TeleMD's telehealth services, employers will reduce insurance premiums, while offering convenient and extensive primary care and mental health support to employees that they can use whenever they need it. Additional services include: (1) Financial and Legal Consultations, (2) Life Coaching, (3) Medical Advocacy and (4) Nutritional Counseling. TeleMd's AI-enhanced platform will offer new ways to provide mental support and care. It will feature Ai Agent that can identify signs of depression or distress and provide on-the-go support, and connect individuals with human therapies when needed. 90% of chronic condition meds home delivered at a $0 copay. 125 acute meds at any pharmacy at a $0copay. TeleMD offers diabetes program at no added cost and OTC meds at a discount. Members save up to 80% on prescriptions; at most major RX retailers as well as 80% on any lab work at any Quest Diagnostics location. Bilingual Services: TeleMD differentiates itself by offering bilingual (English+ Spanish) Board-Certified doctors and mental health therapists. This FREE feature could be a valuable selling point for many corporations with diverse workforces that seek healthcare solutions that cater to employees with varying language needs, presenting a market niche to target. Currently FDA Registered with clinical trials completed. This platform l allows clients to take complete control of everyday health and wellness. Doctegrity is focused on providing (1) affordable telemedicine: cost-effective way for employers to provide healthcare benefits to their employees, including those who may not have traditional insurance coverage, (2) comprehensive solutions and care: their services include 365/24/7 access to board-certified physicians and licensed therapists for both physical and mental health needs and mental health therapists.
お知らせ • May 16Integrated Ventures, Inc. announced delayed 10-Q filingOn 05/15/2025, Integrated Ventures, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 16Integrated Ventures, Inc. announced delayed 10-Q filingOn 11/15/2024, Integrated Ventures, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Sep 30Integrated Ventures, Inc. Auditor Raises 'Going Concern' DoubtIntegrated Ventures, Inc. filed its 10-K on Sep 28, 2022 for the period ending Jun 30, 2022. In this report its auditor, M & K CPAS, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • May 15Integrated Ventures, Inc. Provides Revenue Guidance for the Full Year 2021Integrated Ventures, Inc. provided revenue guidance for the full year 2021. For the year, total revenues for 2021 are projected to be in $2.3 million to $2.4 million range with a 60%+ gross margin.
お知らせ • Jan 24Integrated Ventures, Inc. announced that it expects to receive $3 million in funding from BHP Capital NY, Inc.Integrated Ventures, Inc. (OTCPK:INTV) announced that it has executed a binding term sheet for a private placement of convertible preferred series C stock led by returning investor BHP Capital NY, Inc. for gross proceeds of $3 million on January 22, 2021. The transaction will be completed in tranches and the company expects to receive an initial tranche in next few days. The investor has received a right to convert newly registered preferred stock into common shares at a fixed conversion price of $0.068.
お知らせ • Sep 22Integrated Ventures, Inc. announced that it expects to receive $1 million in funding from Eagle Equities, LLCIntegrated Ventures, Inc. (OTCPK:INTV)announced that it has entered into a securities purchase agreement with Eagle Equities, LLC for private placement of a 6% convertible redeemable note due February 4, 2022 for gross proceeds of $1,000,000 on August 4, 2020. The note will carry a fixed interest coupon of 6% per annum, issued at a discount of 8% and will mature on February 4, 2022. The note provides the holder the right to convert the note into shares of the company’s common stock at a price for each share of common stock equal to the lower of 70% of market price as reported on the National Quotations Bureau OTC Market exchange which the company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the fifteen prior trading days including the day upon which a notice of Conversion is received by the company. The company will receive funding in tranches, $250,000 in its first and second tranche. The company shall not consummate the sale of any convertible securities until the earlier of 30 days after purchase of the second tranche or, if the second tranche is not funded, then 60 days after the closing date of the first tranche. The company will pay $6,000 as legal fees in its first and second tranche. The company issued the note pursuant to exemption provided under Regulation D. On the same day, the company has received its first tranche of $250,000.